PHARMACY

Rite Aid, McKesson ink 10-year distribution deal
Through a new 10-year agreement, McKesson will provide Ride Aid with brand and generic drugs through March 2029.
Novadoz gets FDA green light for generic Rapaflo
Novadoz has received FDA clearance for generic Rapaflo, which is indicated for the symptomatic relief in men experiencing the condition benign prostatic hyperplasia.

Walgreens, Verily partner on health innovation

Walgreens Boots Alliance will be working with Verily, an Alphabet company, on multiple projects under an agreement focused on outcomes for patients with chronic conditions and lowering the cost of care.
AstraZeneca, Merck's Lynparza is approved by FDA

Lynparza is the first PARP inhibitor approved for first-line maintenance in BRCAm advanced ovarian cancer.
Hikma launches generic Ampyra

Hikma is introducing its generic Ampyra, which had a market value of about $543 million in 2017.
Ananda Professional studies CBD’s effect on tapering opioid usage

Ananda Professional announced its sponsorship of a study that showcases how hemp-derived CBD can affect a patient’s willingness to taper their opioid usage in a positive way.
Sandoz, Gan & Lee ink deal to develop insulin biosimilars

Sandoz and Gan & Lee plan to bring biosimilar versions of glargine, lispro and aspart to market.
FDA gives Celltrion, Teva green light for biosimilar Herceptin

The Food and Drug Administration has approved Celltrion and Teva’s biosimilar to Herceptin, Herzuma (trastruzumab-pkrb).
NACDS reacts to Texas Federal District Court’s ruling to strike down ACA

NACDS vows additional advocacy efforts in light of Texas federal district court ruling to strike down the ACA.
FDA gives nod, tentative OK for Lupin's 2 generics

Lupin has received the Food and Drug Administration's OK for generic Onfi, and tentative nod for generic Adcirca, with a value of $601.2 million and $503.8 million, respectively.